journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/27893042/androgen-deprivation-therapy-and-dose-escalated-radiotherapy-for-intermediate-and-high-risk-prostate-cancer-sign-of-changing-times
#1
Deepansh Dalela, Patrick Karabon, Firas Abdollah
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893038/targeting-the-pi3k-akt-mtor-pathway-for-the-treatment-of-mesenchymal-triple-negative-breast-cancer-evidence-from-a-phase-1-trial-of-mtor-inhibition-in-combination-with-liposomal-doxorubicin-and-bevacizumab
#2
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Shelley M Herbrich, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, Nuhad K Ibrahim, James L Murray, Kimberly B Koenig, David Hong, Vivek Subbiah, Razelle Kurzrock, Filip Janku, Stacy L Moulder
Importance: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893034/quality-of-abstracts-reporting-randomized-clinical-trials-presented-at-a-major-oncology-conference
#3
Xu Liu, Yu-Pei Chen, Wen-Fei Li, Ying Sun, Ying Guo, Avraham Eisbruch, Jun Ma
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893031/the-%C3%AE-hpv-subtypes-cornerstone-of-the-next-generation-vaccine
#4
Jad Chahoud, Alyssa G Rieber, Stephen K Tyring
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893029/androgen-deprivation-therapy-and-dose-escalated-radiotherapy-for-intermediate-and-high-risk-prostate-cancer-reply
#5
Aaron D Falchook, Ramsankar Basak, Ronald C Chen
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893028/out-of-pocket-spending-and-financial-burden-among-medicare-beneficiaries-with-cancer
#6
Amol K Narang, Lauren Hersch Nicholas
Importance: Medicare beneficiaries with cancer are at risk for financial hardship given increasingly expensive cancer care and significant cost sharing by beneficiaries. Objectives: To measure out-of-pocket (OOP) costs incurred by Medicare beneficiaries with cancer and identify which factors and services contribute to high OOP costs. Design, Setting, and Participants: We prospectively collected survey data from 18 166 community-dwelling Medicare beneficiaries, including 1409 individuals who were diagnosed with cancer during the study period, who participated in the January 1, 2002, to December 31, 2012, waves of the Health and Retirement Study, a nationally representative panel study of US residents older than 50 years...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893027/errors-in-table
#7
(no author information available yet)
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893021/mitigating-financial-toxicity-among-us-patients-with-cancer
#8
Jonas A de Souza, Rena M Conti
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893016/highlights-in-head-and-neck-cancer
#9
Nicole G Chau, Roy B Tishler, Robert I Haddad
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893009/lymphadenectomy-for-treatment-of-early-stage-endometrial-cancer
#10
Jonathan A Frost, Katie E Webster, Jo Morrison
Clinical Question: What is the association between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with presumed early-stage, low-grade endometrial carcinoma? Bottom Line: The evidence from randomized clinical trials suggests that lymphadenectomy does not improve survival or decrease disease recurrence in women with early-stage, low-grade endometrial carcinoma. Furthermore lymphadenectomy is associated with an increase in both short- and long-term surgery-related systemic morbidity...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893001/association-of-improved-locoregional-control-with-prolonged-survival-in-early-stage-extranodal-nasal-type-natural-killer-t-cell-lymphoma
#11
Yong Yang, Jian-Zhong Cao, Sheng-Min Lan, Jun-Xin Wu, Tao Wu, Su-Yu Zhu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Yu-Jing Zhang, Yuan Zhu, Li-Ming Xu, Zhi-Yong Yuan, Shu-Nan Qi, Ye-Xiong Li
Importance: The long-term survival benefit for radiotherapy (RT) in early-stage extranodal natural killer/T-cell lymphoma (NKTCL) is not known, and it is unclear whether improved locoregional control (LRC) translates into a survival benefit. Objective: To investigate the dose-dependent effect and potential survival benefits of RT on the basis of LRC improvements. Design, Setting, and Participants: Review of clinical data of patients with early-stage NKTCL at 10 institutions in China between 2000 and 2014...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892998/overall-survival-following-neoadjuvant-chemotherapy-vs-primary-cytoreductive-surgery-in-women-with-epithelial-ovarian-cancer-analysis-of-the-national-cancer-database
#12
J Alejandro Rauh-Hain, Alexander Melamed, Alexi Wright, Allison Gockley, Joel T Clemmer, John O Schorge, Marcela G Del Carmen, Nancy L Keating
Importance: Uncertainty remains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC). Objective: To compare overall survival of PCS vs NACT in a large national population of women with advanced-stage EOC. Design, Setting, and Participants: Retrospective cohort study of women with stage IIIC and IV EOC diagnosed between 2003 and 2011 treated at hospitals across the United States reporting to the National Cancer Data Base...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892994/adoption-of-pathologic-complete-response-as-a-surrogate-end-point-in-neoadjuvant-trials-in-her2-positive-breast-cancer-still-an-open-question
#13
Tomasz Burzykowski, Everardo D Saad, Marc Buyse
No abstract text is available yet for this article.
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892992/overall-survival-in-cancer-drug-trials-as-a-new-surrogate-end-point-for-overall-survival-in-the-real-world
#14
Sham Mailankody, Vinay Prasad
No abstract text is available yet for this article.
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892991/surveillance-mammography-in-older-patients-with-breast-cancer-can-we-ever-stop-a-review
#15
Rachel A Freedman, Nancy L Keating, Ann H Partridge, Hyman B Muss, Arti Hurria, Eric P Winer
Importance: Approximately 4% to 5% of breast cancer survivors will develop a new ipsilateral or contralateral cancer (in-breast event) over the 5 years following diagnosis, and annual surveillance mammography is recommended for those with residual breast tissue. The risk for such in-breast events persists over time, though increasing age at cancer diagnosis and treatment with hormonal therapy are associated with lower risk, and most older survivors of breast cancer will ultimately die from nonbreast cancer-related causes...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892988/association-of-molecular-marker-status-with-graded-prognostic-assessment-of-lung-cancer-with-brain-metastases
#16
John H Suh
No abstract text is available yet for this article.
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892986/new-yellow-plaques-in-a-patient-taking-pembrolizumab
#17
Paul R Massey, Krystal M Jones, Matthew C Fox
No abstract text is available yet for this article.
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892985/adoption-of-pathologic-complete-response-as-a-surrogate-end-point-in-neoadjuvant-trials-in-her2-positive-breast-cancer-still-an-open-question-reply
#18
https://www.readbyqxmd.com/read/27892980/ocular-toxicity-of-mitogen-activated-protein-kinase-inhibitors
#19
Robert M J Purbrick, Olaoluwakitan A Osunkunle, Denis C Talbot, Susan M Downes
No abstract text is available yet for this article.
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892978/estimating-survival-in-patients-with-lung-cancer-and-brain-metastases-an-update-of-the-graded-prognostic-assessment-for-lung-cancer-using-molecular-markers-lung-molgpa
#20
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
Importance: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Objective: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases...
November 17, 2016: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"